Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • Biotron Expands into Anaesthetics with Sedarex Acquisition and $2.5m Raise
    Biotron Expands into Anaesthetics with Sedarex Acquisition and $2.5m Raise
    • News

  • DroneShield Boosts Defence Capability with $13 Million Adelaide R&D Investment
    DroneShield Boosts Defence Capability with $13 Million Adelaide R&D Investment
    • News

  • Stakk Secures T-Mobile Contract to Power Super App Expansion
    Stakk Secures T-Mobile Contract to Power Super App Expansion
    • News

  • Medibank Backs Emyria with Landmark Depression Care Deal
    Medibank Backs Emyria with Landmark Depression Care Deal
    • News

  • NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI
    NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI
    • News

  • BRE Wins Final Permit to Advance Rare Earth Pilot Plant in Brazil
    BRE Wins Final Permit to Advance Rare Earth Pilot Plant in Brazil
    • News

  • Harris Technology eyes profitability as refurbished tech sales surge
    Harris Technology eyes profitability as refurbished tech sales surge
    • News

  • QIC Fund Backs Ark Mines with $4.5m to Accelerate Sandy Mitchell Development
    • News

  • Swift Secures $2.4m Chevron Contract to Extend Entertainment and Support Services
    Swift Secures $2.4m Chevron Contract to Extend Entertainment and Support Services
    • News

  • FBR’s tech could help reduce housing construction-related cost pressures
    FBR’s tech could help reduce housing construction-related cost pressures
    • News

Althea to launch low-cost cannabis as medicinal gateway option

  • In News
  • March 29, 2021
  • Conor Murphy
Althea to launch low-cost cannabis as medicinal gateway option

If Australians have reservations about the use of medicinal cannabis to cure their ailments, there will soon be a low-cost option to trial cannabis products, with Althea Group (ASX: AGH) to launch a new range of low dosage oils to give first-time users an affordable entry point.

The new ‘flexi’ cannabis oil products, as the name suggests, provides greater flexibility for patient treatments by not over-prescribing. For example a patient with an intermittent illness will be better suited to this option over Althea’s 50ml-100ml products.

Patients will have the option to trial the flexi option over a 2-3 week titration period, giving themselves and their doctor the ability to determine if further treatment will be needed. This allows Althea to transition positive outcome patients from the low cost flexi option, to one of the Company’s more economical larger sized bottles.

Althea sees this as a way to address the cost barrier seen as an issue for Australian patients, noting that a recent Australian Government inquiry received evidence that cost was one of the biggest barriers for patients struggling to access medicinal cannabis.

“At Althea, we understand that price remains a challenge for many potential new patients that want to trial medicinal cannabis for their conditions. We believe the launch of the new Althea ‘flexi’ 20ml cannabis oil range will be a great way to provide more access to patients via trial size products,” said Althea CEO Joshua Fegan.

“This will in turn build confidence in our medicines and brand as we continue to be the first choice for a growing number of Australia’s medicinal cannabis patients.”

Althea has shown strong growth in the last few years. At the end of 2020 the Company had 12,273 patients in Australia, more than triple the number from the end of 2019.

Revenue growth has reflected this rise in patients, with 175% revenue growth announced for the 31 December 2020 half year on its prior corresponding period.

In the same period Althea posted a loss after income tax of $8.2m, which was attributed to growth related costs that can be expected in such an early stage industry.

  • About
  • Latest Posts
Conor Murphy
Conor Murphy is the Marketing Coordinator at TradersCircle
Latest posts by Conor Murphy (see all)
  • Trading the ASX – Get your head around economic data releases - September 5, 2024
  • Cost cutting is all the rage right now - September 5, 2024
  • Novatti’s strategic moves pave the way for positive cash flow amidst $4m in cost reductions - January 31, 2024
  •  
  •  
  •  
  •  
  • AGH
  • althea
  • asx agh
  • cannabis oil
  • joshua fegan
  • medicinal cannabis
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Conor Murphy
Conor Murphy is the Marketing Coordinator at TradersCircle
Latest posts by Conor Murphy (see all)
  • Trading the ASX – Get your head around economic data releases - September 5, 2024
  • Cost cutting is all the rage right now - September 5, 2024
  • Novatti’s strategic moves pave the way for positive cash flow amidst $4m in cost reductions - January 31, 2024

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Conor Murphy
Conor Murphy is the Marketing Coordinator at TradersCircle
Latest posts by Conor Murphy (see all)
  • Trading the ASX – Get your head around economic data releases - September 5, 2024
  • Cost cutting is all the rage right now - September 5, 2024
  • Novatti’s strategic moves pave the way for positive cash flow amidst $4m in cost reductions - January 31, 2024
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.